AP1-Luc/EF1α-mCherry Reporter Cell Line - HEK293

AP1-Luc/EF1α-mCherry Reporter Cell Line - HEK293 is a human embryonic kidney 293 cell line engineered to provide sensitive, dual-function reporting of activator protein 1 (AP-1) pathway activity. The cells contain a luciferase reporter gene under the control of AP-1-responsive elements, enabling quantitative measurement of AP-1-dependent transcriptional activation through luminescence detection. In parallel, constitutive expression of mCherry driven by the human EF1α promoter provides a robust fluorescent marker for cell identification, monitoring, and normalization. AP-1 is a transcription factor complex primarily composed of proteins from the Jun, Fos, ATF, and MAF families and is involved in the regulation of cellular proliferation, differentiation, stress responses, inflammation, and apoptosis. The HEK293 background offers reliable growth characteristics, high transfection compatibility, and convenient handling in standard cell culture conditions. This reporter cell line is designed to deliver reproducible AP-1 signaling readouts while allowing rapid visual confirmation of cell presence and quality through red fluorescence.

The AP1-Luc/EF1α-mCherry Reporter Cell Line - HEK293 is suitable for screening compounds that modulate the AP-1 signaling pathway, including kinase inhibitors, anti-inflammatory agents, oxidative stress inducers, cytokine-related modulators, and potential anti-cancer drug candidates. It can be used to investigate upstream signaling pathways (such as the MAPK/ERK, JNK, and p38 pathways) as well as receptor-mediated responses triggered by growth factors, inflammatory stimuli, or environmental stress. Luciferase activity assays provide a sensitive and scalable endpoint for dose-response studies, pathway analysis, and high-throughput screening, while mCherry fluorescence facilitates cell tracking, optimization of experimental conditions, and the assessment of treatment-related cytotoxicity or cell loss. In addition, this cell line can be used to validate gene targets, assess the functional consequences of gene overexpression or knockdown experiments, and characterize biological agents or small-molecule drugs that affect AP-1-mediated transcription.